Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Sanofi is teaming with Verily on a $500M JV aimed at marrying tech with diabetes drugs
9 years ago
Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts
9 years ago
Startups
Low-profile Thar Pharma takes a $50M flier on a weak IPO market
9 years ago
From boom to swoon: Biotech IPOs fade fast in Q2
9 years ago
R&D
Q2 venture investing slows a tad, but the big money still flows into biotech
9 years ago
R&D
The biotech IPO feast flags as investors lose their appetite for R&D risk
9 years ago
IPO bound? CRISPR Therapeutics ups B round to a cool $140M
9 years ago
Pharma
$121M later, Langer-backed Selecta raises $70M more from its IPO
9 years ago
Antifungal player F2G banks $60M, eyes IPO in leadup to a PhIII trial
9 years ago
R&D
First page
Previous page
143
144
145
146